ALS Drugs: FDA May Adjust Development Recommendations In Real Time For Ongoing Programs

 
• By Sue Sutter

Agency’s action plan for rare neurodegenerative diseases maps out over five years, but knowledge gained can inform products currently in development; new FDA grant program looks to invest in remote use of clinical outcome assessments for amyotrophic lateral sclerosis.

Real time
Lessons learned from activities under FDA's ALS Science Strategy may be applied in real time to ongoing development programs. • Source: Shutterstock

More from Approval Standards

More from Pathways & Standards